Memorandum of Agreement ("MoA") was signed on 13 December 2019 between Philab Holdings Corporation and Prenetics Limited, of Hong Kong, giving Philab Holdings Corporation an exclusive license for the Philippines to market, sell and provide certain Prenetic genetics testing services. This exclusive license helps Philab Holdings Corporation meet its mission of bringing accessible, affordable and accurate healthcare to all Filipinos, including the very latest medtech innovations. The Prenetic genetics testing services licensed include (1) the CircleDNA suite of services, the world's most comprehensive DNA test, utilizing whole exome sequencing technology, delivering over 500+ reports with just one saliva sample, and (2) ColoClear, Asia's first non-invasive stool-based DNA test to screen for colon cancer with 92% sensitivity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | -1.37% | -5.11% | -2.54% |
21/05 | Prenetics Global Limited Announces Committee Resignations | CI |
01/04 | Prenetics Global Limited Reports Impairment Loss of Goodwill for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.54% | 70.37M | |
-32.63% | 9.2B | |
-5.66% | 3.12B | |
+23.12% | 2.8B | |
-17.75% | 2.05B | |
-24.39% | 1.59B | |
+65.65% | 1.44B | |
+32.83% | 830M | |
-6.55% | 720M | |
-29.80% | 507M |
- Stock Market
- Equities
- PRE Stock
- News Prenetics Global Limited
- Philab Holdings Corporation and Prenetics Limited Sign Memorandum of Agreement